Nanotechnology is the design and assembly of submicroscopic devices called nanoparticles, which are 1-100 nm in diameter. Nanomedicine is the application of nanotechnology for the diagnosis and treatment of human disease. Disease-specific receptors on the surface of cells provide useful targets for nanoparticles. Because nanoparticles can be engineered from components that (1) recognize disease at the cellular level, (2) are visible on imaging studies, and (3) deliver therapeutic compounds, nanotechnology is well suited for the diagnosis and treatment of a variety of diseases. Nanotechnology will enable earlier detection and treatment of diseases that are best treated in their initial stages, such as cancer. Advances in nanotechnology will also spur the discovery of new methods for delivery of therapeutic compounds, including genes and proteins, to diseased tissue. A myriad of nanostructured drugs with effective site-targeting can be developed by combining a diverse selection of targeting, diagnostic, and therapeutic components. Incorporating immune target specificity with nanostructures introduces a new type of treatment modality, nano-immunochemotherapy, for patients with cancer. In this review, we will discuss the development and potential applications of nanoscale platforms in medical diagnosis and treatment. To impact the care of patients with neurological diseases, advances in nanotechnology will require accelerated translation to the fields of brain mapping, CNS imaging, and nanoneurosurgery. Advances in nanoplatform, nano-imaging, and nano-drug delivery will drive the future development of nanomedicine, personalized medicine, and targeted therapy. We believe that the formation of a science, technology, medicine law-healthcare policy (STML) hub/center, which encourages collaboration among universities, medical centers, US government, industry, patient advocacy groups, charitable foundations, and philanthropists, could significantly facilitate such advancements and contribute to the translation of nanotechnology across medical disciplines.

Peptide-drug-conjugates (PDCs) are being developed as an effective strategy to specifically deliver cytotoxic drugs to cancer cells. However one of the challenges to their successful application is the relatively low stability of peptides in the blood, liver and kidneys. Since AuNPs seem to have a longer plasma half-life than PDCs, one approach to overcoming this problem would be to conjugate the PDCs to gold nanoparticles (AuNPs), as these have demonstrated favorable physico-chemical and safety properties for drug delivery systems. We set out to test whether PEG coated-AuNPs could provide a suitable platform for the non-covalent loading of pre-formed PDCs and whether this modification would affect the bioavailability of the PDCs and their cytotoxicity toward target cancer cells.Peptides specifically internalized by A20 murine lymphoma cells were isolated from a phage library displaying 7mer linear peptides. Peptide specificity was validated by flow cytometry and confocal microscopy. PDCs were synthesized containing a selected peptide (P4) and either chlorambucil (Chlor), melphalan (Melph) or bendamustine (Bend). Gold nanoparticles were sequentially coated with citrate, PEG-6000 and then PDC (PDC-PEG-AuNP). The physico-chemical properties of the coated particles were analyzed by electrophoresis, TEM, UV-VIS and FTIR. Stability of free and PDC-coated AuNP was determined.Biopanning of the phage library resulted in discovery of several novel peptides that internalized into A20 cells. One of these (P4) was used to synthesize PDCs containing either Chlor, Melph or Bend. All three PDCs specifically killed A20 target cells, however they had short half-lives ranging from 10.6 to 15.4 min. When coated to PEG-AuNPs, the half-lives were extended to 21.0-22.3 h. The PDC-PEG-AuNPs retained cytotoxicity towards the target cells. Moreover, whereas pre-incubation for 24 h of free PDCs almost completely abolished their cytotoxic activity, the PDC-PEG-AuNPs were still active even after 72 h pre-incubation.Peptide-drug-conjugates hold potential for improving the target efficacy of chemotherapeutic drugs, however their short half-lives may limit their application. This hurdle can be overcome by easily conjugating them to gold nanoparticles. This conjugation also opens up the possibility of developing slow release formulations of targeted drug delivery systems containing PDCs.

Recent advances in nanotechnology and biotechnology have contributed to the development of engineered nanoscale materials as innovative prototypes to be used for biomedical applications and optimized therapy. Due to their unique features, including a large surface area, structural properties, and a long circulation time in blood compared with small molecules, a plethora of nanomaterials has been developed, with the potential to revolutionize the diagnosis and treatment of several diseases, in particular by improving the sensitivity and recognition ability of imaging contrast agents and by selectively directing bioactive agents to biological targets. Focusing on cancer, promising nanoprototypes have been designed to overcome the lack of specificity of conventional chemotherapeutic agents, as well as for early detection of precancerous and malignant lesions. However, several obstacles, including difficulty in achieving the optimal combination of physicochemical parameters for tumor targeting, evading particle clearance mechanisms, and controlling drug release, prevent the translation of nanomedicines into therapy. In spite of this, recent efforts have been focused on developing functionalized nanoparticles for delivery of therapeutic agents to specific molecular targets overexpressed on different cancer cells. In particular, the combination of targeted and controlled-release polymer nanotechnologies has resulted in a new programmable nanotherapeutic formulation of docetaxel, namely BIND-014, which recently entered Phase II clinical testing for patients with solid tumors. BIND-014 has been developed to overcome the limitations facing delivery of nanoparticles to many neoplasms, and represents a validated example of targeted nanosystems with the optimal biophysicochemical properties needed for successful tumor eradication.

Nanomedicines play an important role in cancer therapy; however, some drawbacks including unsatisfactory efficacy and side effects arising from indiscriminate drug release retard their clinical applications. Although functionalization of nanomedicines through covalent interactions can improve the pharmacokinetics and efficacy of the loaded drugs, complicated and tedious synthesis greatly limits the exploration of multifunctional nanoparticles. Herein, we utilize a supramolecular strategy to design a nanomedicine for targeted drug delivery through cucurbit[8]uril-based host–guest ternary complexation and successfully prepare prostate-specific membrane antigen (PSMA)-targeted supramolecular nanoparticles encapsulating doxorubicin (DOX). In vitro studies exhibit targeted modification via noncovalent enhance anticancer efficiency of DOX due to the increased cell uptake on account of receptor-mediated endocytosis. This design provides a new strategy for the development of sophisticated drug delivery systems and holds perspective potentials in precise cancer treatments.

The report covers Targeted Liposomes Drug Delivery Market Trends and the Market is Segmented by Technology (Nanocrystals, Nanoparticles, Liposomes, Micelles, Others), Application (Neurology, Oncology, Cardiovascular/Physiology, Anti-inflammatory/Immunology, Anti-infective, Other Applications) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The market provides the value (in USD million) for the above-mentioned segments.

Responses to molecularly targeted therapies can be highly variable and depend on mutations, fluctuations in target protein levels in individual cells, and drug delivery. The ability to rapidly quantitate drug response in cells harvested from patients in a point-of-care setting would have far reaching implications. Capitalizing on recent developments with miniaturized NMR technologies, we have developed a magnetic nanoparticle-based approach to directly measure both target expression and drug binding in scant human cells. The method involves covalent conjugation of the small-molecule drug to a magnetic nanoparticle that is then used as a read-out for target expression and drug-binding affinity. Using poly(ADP-ribose) polymerase (PARP) inhibition as a model system, we developed an approach to distinguish differential expression of PARP in scant cells with excellent correlation to gold standards, the ability to mimic drug pharmacodynamics ex vivo through competitive target-drug binding, and the potential to perform such measurements in clinical samples.

Breast cancer is conventionally treated by surgery, chemotherapy and radiation therapy followed by post operational hormonal therapy. Tamoxifen citrate is a best option to treat breast cancer because its selective estrogen receptor modulation activity. Owing to its antiestrogenic action on breast as well as uterine cells, Tamoxifen citrate shows uterine toxicity. The dose 20 mg per day of Tamoxifen citrate required to show therapeutic effect causes side effects and toxicity to vital organs such as liver, kidney and uterus. In the present study, transferrin-conjugated solid lipid nanoparticles (SLNs) were successfully prepared to enhance the active targeting of tamoxifen citrate in breast cancer. Developed formulations were evaluated for particle size, surface charge, surface morphology and in vitro dissolution studies. Developed formulations exhibited more cytotoxicity as compared to pure Tamoxifen citrate solution in time as well as concentration dependent manner on human breast cancer MCF-7 cells. Further, cell uptake and flow cytometry studies confirmed the qualitative uptake of developed D-SLN and SMD-SLN by human breast cancer MCF-7 cells. Overall, proposed study highlights that transferrin engineered nanocarriers could enhance the therapeutic response of nanomedicines for breast cancer treatment.

FT-IR and NMR of the polymer

Nanotechnology has many potential applications in cancer treatment. For example, nano-drug delivery systems (NDDS) with high bioavailability, biodegradability, and biocompatibility have been developed, in order to increase the therapeutic effects of anti-cancer drugs. Among these NDDS, high-performance hydroxyapatite nanoparticles are rapidly advancing in the targeted cancer treatment due to their numerous benefits. Curcumin is a herbal metabolite that acts as a chemical inhibitor through the inhibition of tumor cells and the progression of many cancers. However, the poor bioavailability of curcumin is the most important challenge in using this substance. In this study, hydroxyapatite nanoparticles coated by chitosan were used as a pH-sensitive biopolymer to improve the efficiency and bioavailability of curcumin. For this purpose, hydroxyapatite nanoparticles were first synthesized by the sol-gel method. Then, a layer of chitosan was coated on it, and the curcumin drug was encapsulated in the nanocarrier, under controlled conditions. Techniques such as SEM, XRD, and FTIR were used to characterize the nanocarriers. In the second part, nano-drugs prepared by various bioassays were examined. For this purpose, the rate of cytotoxicity by the MTT method and the rate of apoptosis induction by the AO/ET staining method on the brain carcinoma U87MG cell line were investigated.

Nanoparticles provide new fields for life medical science application, including targeted-drug delivery and cancer treatment. To maximize the delivery efficiency of nanoparticle, one must understand the uptake mechanism of nanoparticle in cells, which may determine their ultimate fate and localization in cells. Recently, the proposed-cancer stem cell (CSC) theory has been attracted great attention and regarded as new targets for the new nanodrug developmet and cancer therapies. The interaction between nanoparticles and cancer cells has been extensively studied, but the uptake mechanism of nanoparticles in CSCs has received little attention. Here, we use the pharmacological inhibitors of major endocytic pathways to study the silica nanoparticle (SiNP) uptake mechanisms in the human breast adenocarcinoma cell line (MCF-7) and MCF-7-derived breast cancer stem cells (BCSCs). The results demonstrate that the uptake of SiNPs, particularly amino-functionalized SiNPs, in MCF-7 cells is strongly affected by the actin depolymerization, whereas BCSCs more strongly inhibit the amino-functionalized SiNP uptake after the scavenger receptor disruption. These findings indicate a distinct endocytic mechanism of functionalized SiNPs in BCSCs, which is significant for designing ideal nanosized drug delivery systems and improving the selectivity for CSC-targeted therapy.

Chitosan nanoparticles can advance the pharmacological and therapeutic properties of chemotherapeutic agents by controlling release rates and targeted delivery process, which eliminates the limitations of conventional anti-cancer therapies and they are also safe as well as cost-effective. The aim of present study is to explore the anti-tumour effect of niclosamide in lung and breast cancer cell lines using biocompatible and biodegradable carrier where nanoparticles loaded with hydrophobic drug (niclosamide) were synthesized, characterized and applied as a stable anti-cancer agent. Niclosamide loaded chitosan nanoparticles (Nic-Chi Np's) of size approximately 100–120 nm in diameter containing hydrophobic anti-cancer drug, i.e. niclosamide, were prepared. Physico-chemical characterization confirms that the prepared nanoparticles are spherical, monodispersed and stable in aqueous systems. The therapeutic efficacy of Nic-Chi Np's was evaluated against breast cancer cell line (MCF-7) and human lung cancer cell line (A549). MTT assay reveals the cell viability of the prepared Nic-Chi Np's against A549 and MCF-7 cells and obtained an IC50 value of 8.75 µM and 7.5 µM, respectively. Acridine orange/ethidium bromide dual staining results verified the loss of the majority of the cells by apoptosis. Flow cytometer analysis quantified the generation of intracellular reactive oxygen species (ROS) and signified that exposure to a higher concentration (2 × IC50) of Nic-Chi Np's resulted in elevated ROS generation. Notably, Nic-Chi Np treatment showed more apoptosis and cell death in MCF-7 as compared to A549. Further, the remarkable induction of apoptosis by Nic-Chi Np's was confirmed by semi-quantitative reverse transcription polymerase chain reaction, scanning electron microscopy and cell-cycle analysis. Thus, Nic-Chi Np's may have a great potential even at low concentration for anti-cancer therapy and may replace or substitute more toxic anti-mitotic drugs in the near future.

The Global Advanced And Targeted Drug Delivery Market Size are expected to grow at a CAGR of 14.3% during the forecast period, 2021-2028. this growth will be driven by factors such as increasing focus on improving patient compliance, growing adoption of novel technologies in the development pipeline, and rise in R&D expenditure for developing new products and therapies. Drug delivery systems are considered an important factor for the treatment process because they can provide proper dosage to patients with minimal side effects.

Advanced Drug Delivery is the system that can produce a therapeutic response in any target area of the human body. It also enables one to obtain the maximum benefit from their medicine by reducing side effects and increasing patient compliance. Global advanced & targeted drug.

On the basis of Types, the market is segemtned into Liposomes, Microspheres, Nanoparticles, and Emulsion.

Liposomes:

Liposomes are microscopic spheres that consist of one or more lipid bilayers and an aqueous interior. They contain encapsulated water-soluble pharmaceutical agents, such as hydrophilic drugs (e.g., proteins) and organic solvents with high affinity to the liposome membrane surface.

Microspheres:

Microspheres are small spherical units of solid material. They can be prepared with controlled size and shape, which varies from nanometre to millimeters in diameter. Some microsphere types also contain internal pores or channels for drug release rate control. The Microsphere encapsulation method allows the drugs to be released over a specific period of time.

Nanoparticles:

Nanoparticles are tiny particles that resemble the size of molecules. They can be as small as 100 nanometers (nm). The nanoparticle is considered to be a very promising therapeutic and imaging modality in medicine because it has the potential for many unique properties including Enhanced solubility, stability, and permeability across membranes.

Emulsion:

An emulsion is a mixture of two or more liquids that are normally immiscible (unmixable or unblendable). Emulsions contain both oil and water-based components, which generally do not mix well with each other. However, small amounts of surfactant will allow the oils to form droplets.

On the basis of Application, the market is segemtned into Clinic and Hospital.

Clinic:

The use of Advanced & Targeted Drug Delivery is in clinics are used for the treatment, cure, or prevention of diseases. The clinics market will be increased with the rising number of chronic disorders such as cancer and cardiovascular disease which require regular administration of medication.

Hospital:

In hospitals, there are a number of drug delivery systems that have been used to administer drugs. These include implantable devices such as pumps and catheters for continuous administration of medication over an extended period. In addition, injectables for acute care settings represent another significant market segment due to the high prevalence of chronic diseases in hospitals.

On the basis of Region, the market is segemtned into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. The market in North America is expected to account for the largest share of the global advanced and targeted drug delivery market throughout the forecast period. North America is estimated to hold the largest market share in 2021, while APAC would grow at the highest CAGR during the forecast period. In terms of value, the market is segmented into North America and Europe. In 2021, North America holds a major share in the global Advanced & Targeted Drug Delivery Market with the highest CAGR from 2021 to 2028. In 2021, North America occupied the leading position in the global advanced & targeted drug delivery market and is expected to maintain its dominance throughout the forecast period. The market is expected to reach up to $xx million by 2028. of the advanced & targeted drug delivery system, liposomes hold maximum share in 2021 and are anticipated to retain their lead position throughout the forecast period. in the Latin American region. is estimated to grow at a higher CAGR in the forecast period. Microspheres are expected to have the highest market share by 2028 among other advanced & targeted drug delivery systems types. of advanced and targeted drug delivery system, Liposomes hold maximum share in 2021 and are anticipated to retain their lead position throughout the forecast period.

Dacarbazine (DTIC) dominates chemotherapy for malignant melanoma (MM). However, the hydrophobicity, photosensitivity, instability, and toxicity to normal cells of DTIC limit its efficacy in treating MM. In the present study, we constructed star-shaped block polymers nanoparticles (NPs) based on Cholic acid -poly (lactide-co-glycolide)-b-polyethylene glycol (CA-PLGA-b-PEG) for DTIC encapsulation and MM targeted therapy. DTIC-loaded CA-PLGA-b-PEG NPs (DTIC-NPs) were employed to increase the drug loading and achieve control release of DTIC, followed by further modification with nucleic acid aptamer AS1411 (DTIC-NPs-Apt), which played an important role for active targeted therapy of MM. In vitro, DTIC-NPs-Apt showed good pH-responsive release and the strongest cytotoxicity to A875 cells compared with DTIC-NPs and free DTIC. In vivo results demonstrated that the versatile DTIC-NPs-Apt can actively target the site of MM and exhibited excellent anti-tumor effects with no obvious side effects. Overall, this research provided multi-functional NPs, which endow a new option for the treatment of MM.

This data is used in the PhD thesis "Dendrimer nanoparticles in anticancer treatment applications" and contain the findings about in vitro and in vivo efficacy and toxicity of dendrimer-enhanced small molecules and siRNAs. We used dendrimer nanoparticles as anti-LMP1 siRNA carriers for nasopharyngeal carcinoma targeted therapy, and applied bola-lipid dendrimers as vehicles for imatinib mesylate to successfully inhibit ovarian cancer stem cells, both in vitro and in vivo, without serious adverse effects.

Snapshot img

RNAi Drug Delivery Market Forecast 2023-2027

The RNAi drug delivery market size is estimated to grow by USD 109.73 billion at a CAGR of 20.83% between 2022 and 2027. The high target affinity and specificity of RNAi therapeutics make them attractive for treating a wide range of diseases, including neurological disorders. Increasing research activities in the pharmaceutical and biotechnology sectors are leading to the development of new RNAi therapeutics and expanding their applications. The increasing prevalence of neurological disorders, such as Alzheimer's and Parkinson's disease, is driving the demand for effective treatments, further fueling market growth in this area.

It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

What will be the size of the Market During the Forecast Period?

To learn more about this report, View Report Sample

Market Segmentation

This market report extensively covers market segmentation by technology (nanoparticle drug delivery, pulmonary drug delivery, nucleic acid drug delivery, and aptamer drug delivery), application (infectious diseases, oncology, cardiology, neurology, and others), and geography (North America, Europe, Asia, and Rest of World (ROW)).

By Technology

The market share growth by the nanoparticle drug delivery segment will be significant during the forecast period. Nanoparticle drug delivery systems are modern technologies that are rapidly developing technology materials in the nanoscale range and are employed to serve as therapeutic agents to targeted sites in a controlled manner. Nanotechnology provides numerous advantages in the treatment of chronic human diseases by delivering precise medications to specified locations and targets.

Get a glance at the market contribution of various segments View the PDF Sample

The nanoparticle drug delivery segment showed a gradual increase in the market share of USD 12.45 billion in 2017. Characteristics of nanoparticles, such as distinctive size, are useful for the efficient delivery of RNAi therapeutics. As a result, nanoparticle drug delivery systems are used in the treatment of cancer, and it is an emerging therapeutic strategy for combating cancer. Thus, the application of nanoparticle drug delivery systems in cancer treatment coupled with the increasing cases of cancer will drive the growth of the segment and, in turn, the market in focus during the forecast period

By Region

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. In North America, there is a rise in the number of cancer and metabolic diseases due to excessive smoking and consumption of alcohol. The availability of improved diagnostic modalities has made it possible to identify several rare diseases, as a result of which many market vendors, along with researchers, are discovering and coming up with RNAi therapies.

Currently, RNAi drug delivery is having high demand in the US. The region has highly advanced research and manufacturing facilities, which is one of the reasons for the high growth rate of the market in North America. For example, in April 2020, Alnylam entered a development and commercialization collaboration with the Dicerna subsidiary of Novo Nordisk to advance investigational RNAi therapeutics for the treatment of alpha-1 liver disease. Such factors will drive the growth of the market during the forecast period.

Market Dynamics and Customer Landscape

The market is experiencing rapid growth, fueled by advancements in nanoparticle-based delivery systems and aptamer drug delivery technology. These innovations are enhancing the efficacy of molecular diagnostics and personalized medicine for various conditions, including autoimmune hepatitis, ocular disorders, and oncology. With the global population aging, there is a rising need for targeted therapies to address metabolic disorders and malignancies. The use of artificial intelligence in drug development is also gaining traction, as seen in the development of drugs like Atorvastatin Calcium. These trends underscore the significant potential of RNAi in revolutionizing pharmaceuticals for a range of diseases. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver

The high target affinity and specificity of RNAi therapeutics are the key drivers for the growth of the market.

RNAi therapeutics demonstrate remarkable effectiveness against their specific targets

Nanotechnology in Drug Delivery Market Report 2024, Market Size, Share, Growth, CAGR, Forecast, Revenue, list of Nanotechnology in Drug Delivery Companies (Access Pharmaceuticals, Alkermes, Aquanova, Camurus, Capsulution Pharma, Celgene), Market Segmented by Application (Cancer, Tumor, Other), by Type (Targeted Delivery, Drug Package)

The development of multidrug resistance (MDR) has become an increasingly serious problem in cancer therapy. The cell-membrane overexpression of P-glycoprotein (P-gp), which can actively efflux various anticancer drugs from the cell, is a major mechanism of MDR. Nuclear-uptake nanodrug delivery systems, which enable intranuclear release of anticancer drugs, are expected to address this challenge by bypassing P-gp. However, before entering the nucleus, the nanocarrier must pass through the cell membrane, necessitating coordination between intracellular and intranuclear delivery. To accommodate this requirement, we have used DNA self-assembly to develop a nuclear-uptake nanodrug system carried by a cell-targeted near-infrared (NIR)-responsive nanotruck for drug-resistant cancer therapy. Via DNA hybridization, small drug-loaded gold nanoparticles (termed nanodrugs) can self-assemble onto the side face of a silver-gold nanorod (NR, termed nanotruck) whose end faces were modified with a cell type-specific internalizing aptamer. By using this size-photocontrollable nanodrug delivery system, anticancer drugs can be efficiently accumulated in the nuclei to effectively kill the cancer cells.

Market Overview:

The Global Nanopharmaceuticals Market Size is expected to grow at a CAGR of XX% from 2022 to 2030. The growth in the market can be attributed to factors such as rising prevalence of chronic diseases, increasing demand for targeted drug delivery, and technological advancements in the field of nanotechnology. Based on type, the global nanopharmaceuticals market is segmented into Liposomes, polymeric micelles, solid lipid nanoparticles (SLN), microemulsion and Nanoemulsion, and nanosuspension. Liposomes are expected to dominate the market during the forecast period owing to their ability to encapsulate large payloads of drugs and their low toxicity. Based on application, cancer and tumor is expected to be the largest segment during the forecast period owing to rising incidence of cancer across the globe.

Product Definition:

Nanopharmaceuticals are drugs that have been designed to work at the nanoscale, or one billionth of a meter. Nanopharmaceuticals can be made up of nanoparticles, which are tiny particles just a few nanometers in size. These tiny particles can improve the delivery and effectiveness of drugs by targeting specific areas in the body where they're needed most.

Liposomes:

Liposomes are small vesicular structures composed of phospholipids and water. They are naturally occurring membrane-bounded lipid particles that are commonly used as drug delivery systems in the pharmaceutical industry. Liposomes can be administered orally, vaginally or rectally; they can also be injected intravenously, intraperitoneally or intramuscularly.

Polymeric Micelles:

Polymeric micelles are colloidal systems formed by the association of multiple polymers. They have a wide range of applications in pharmaceuticals, cosmetics, and food industry. Polymeric micelles help to improve the absorption properties and bioavailability of drug molecules which is an essential step for drug development process.

Solid Lipid Nanoparticles:

Solid lipid nanoparticles (SLNs) are tiny solid particles composed of cholesterol, phospholipids, and other biological molecules. SLNs have many potential uses in nanopharmaceuticals because they are small enough to get through the blood-brain barrier, and they can carry drugs directly to the brain or other organs.

Microemulsion and Nnanoemulsion:

Microemulsion, nanoemulsion and their various uses in nanopharmaceuticals are miniature dispersions of water, oil or other liquid substances that can be easily divided into small droplets. These formulations help to improve the delivery of drug molecules to targeted areas within the body. They can also reduce the risk of side effects caused by drug interactions or poor absorption rates.

Nanosuspension:

Nanosuspension is a method for dispersing nanoparticles in water or other media. Nanosuspensions can be used to improve the efficiency of drug delivery, distribution, and absorption into the body.

Application Insights:

The cancer and tumor segment dominated the global nanopharmaceuticals market, accounting for over 40% of the overall revenue share. The increasing prevalence of cancer is one of the major factors contributing to this growth. Solid lipid nanoparticles (SLN) have shown potential as a novel therapeutic tool for various cancers such as lung, breast and liver among others due to their enhanced permeability into cells compared to other drugs currently used for treatment purposes. In addition, they can be easily modified by attaching molecules which may help enhance their efficacy even further leading to reduced side effects associated with them making them an ideal drug delivery system candidate within targeted therapy applications. Nanopharmaceuticals may be used as treatments for autoimmune disorders, such as rheumatoid arthritis and lupus. Nanotechnology can help to target specific immune cells and reduce inflammation. There are several potential uses of nanopharmaceuticals in inflammation. They can be used to treat the underlying cause of the inflammation, and/or to improve symptoms. They may also be used as adjuvants in medical treatments designed to reduce inflammation.

Regional Analysis:

North America dominated the global nanopharmaceuticals market in terms of revenue share at over 38.0%. Asia Pacific region is anticipated to witness lucrative CAGR during the forecast period owing to factors such as growing economy, rising disposable income levels, expanding healthcare infrastructure along with increasing investments by governments & private entities for developing novel therapie

Multifunctional supramolecular nanoplatforms that integrate the advantages of different therapeutic techniques can trigger multimodal synergistic treatment of tumors, thus representing an emerging powerful tool for cancer therapeutics. Methods: In this work, we design and fabricate a multifunctional supramolecular drug delivery platform, namely Fa-mPEG@CP5-CuS@HMSN-Py nanoparticles (FaPCH NPs), consisting of a pyridinium (Py)-modified hollow mesoporous silica nanoparticles-based drug reservoir (HMSN-Py) with high loading capacity, a layer of NIR-operable carboxylatopillar[5]arene (CP5)-functionalized CuS nanoparticles (CP5-CuS) on the surface of HMSN-Py connected through supramolecular host-guest interactions between CP5 rings and Py stalks, and another layer of folic acid (Fa)-conjugated polyethylene glycol (Fa-PEG) antennas by electrostatic interactions capable of active targeting at tumor lesions, in a controlled, highly integrated fashion for synergistic chemo-photothermal therapy. Results: Fa-mPEG antennas endowed the enhanced active targeting effect toward cancer cells, and CP5-CuS served as not only a quadruple-stimuli responsive nanogate for controllable drug release but also a special agent for NIR-guided photothermal therapy. Meanwhile, anticancer drug doxorubicin (DOX) could be released from the HMSN-Py reservoirs under tumor microenvironments for chemotherapy, thus realizing multimodal synergistic therapeutics. Such a supramolecular drug delivery platform showed effective synergistic chemo-photothermal therapy both in vitro and in vivo. Conclusion: This novel supramolecular nanoplatform possesses great potential in controlled drug delivery and tumor cellular internalization for synergistic chemo-photothermal therapy, providing a promising approach for multimodal synergistic cancer treatment.